You are here

Xarelto

J&J's bid to change pay model for Stelara, Xarelto slammed

Pharmaphorum

Mon, 08/26/24 - 10:16 am

3 patent expirations in 2024 and how companies are pivoting

Pharma Voice

Wed, 04/17/24 - 11:13 am

Bayer's patent for blood thinner Xarelto invalid, UK court rules

Reuters

Fri, 04/12/24 - 11:06 am

J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses

Fierce Pharma

Tue, 11/14/23 - 09:56 pm

peripheral artery disease

Anthos hails win over Xarelto with novel anticoagulant

Pharmaphorum

Mon, 09/18/23 - 09:56 am

Anthos Therapeutics

clinical trials

atrial fibrillation

Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD

Clinical Trials Arena

Mon, 03/13/23 - 10:03 am

real world data

atrial fibrillation

ESC 2022 preview – who’s got the XI factor?

EP Vantage

Tue, 08/23/22 - 10:23 am

Bristol Myers Squibb

Did J&J and BMS conspire on blood thinner price hikes? Congressional leaders want DOJ, FTC to look into it: report

Fierce Pharma

Tue, 06/14/22 - 08:57 pm

Bristol Myers Squibb

With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?

Fierce Pharma

Tue, 03/1/22 - 10:04 pm

J&J, Bayer's Xarelto scores FDA nod in post-surgery artery disease as partners try to catch up with Eliquis

Fierce Pharma

Tue, 08/24/21 - 10:54 pm

Bristol Myers Squibb

ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients

Fierce Pharma

Sun, 05/16/21 - 11:32 pm

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it's better than expected

Fierce Pharma

Wed, 03/10/21 - 10:49 pm

ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study

Fierce Pharma

Mon, 08/31/20 - 10:49 am

Bristol-Myers Squibb

site-specific bleeding

ACC: J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery

Fierce Pharma

Sat, 03/28/20 - 11:27 pm

clinical trials

peripheral artery disease

J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER

Endpoints

Fri, 10/18/19 - 10:18 am

FDA OKs new use for J&J's Xarelto

Seeking Alpha

Mon, 10/14/19 - 09:55 am

venous thromboembolism

Xarelto falls into the donut hole

Biopharma Dive

Tue, 07/16/19 - 11:05 pm

J&J Takes Hits on Talc Lawsuit, Settles Xarelto Suit, Faces Pricing Criticism

BioSpace

Fri, 05/10/19 - 05:56 pm

Bayer, J&J's Xarelto scripts stagnate as discounts, competition pile up

Fierce Pharma

Tue, 04/23/19 - 12:10 pm

Bristol-Myers Squibb

Pages